Supply of Pharmaceuticals in the West Bank and Gaza Strip by Birzeit University. Institute of Community and Public Health
Supply of Pharmceuticals in the West Bank and Gaza Strip 
 
 
Commissioned by UNICEF, the Department of Community Health at Birzeit 
University conducted a survey of available supplies of pharmaceuticals in the 
West Bank and Gaza Strip in 1992. Surveying local, Israeli, and international 
manufacturing companies, including governmental, UNRWA and commercial 
outlets, we were able to develop a list of available pharmaceuticals. Utilizing 
provided lists of sales or dispensation, we were also able to estimate an 
approximate total cost for medications in the country for the year 1991. 
 
Proceeding to classify these pharmaceuticals based on their composition, and 
utilizing the WHO standards for the development of a rational drug list, we were 
able to note the following: 
 
1. Generally speaking, there is a very large number of brand and generic 
products on the market, and most definitely un-warranted by need: 
 
* Palestinian pharmaceutical companies alone produced 635 brands 
* There were 411 Israeli manufactured brand names in the market at the time 
* There were 580 internationally manufactured brands available in the market at 
the time 
 
In total:  at least 1626 brands were available during that year. Of those, there 
were at least 1035 generic medications, or at least 5 times more than what is 
recommended by the world Health Organizations. This raises questions as to the 
necessity of having so many brands of the same medication, and raising 
questions as to the impact of this on health economics and financing on the one 
hand, and the potential confusion in prescribing and consumption it can create. 
 
2. Of the total number of brand name medications available, 39% were made 
locally, 25% were imported from Israel and 36% from abroad. Duplication was 
evident with antibiotics, most notably ampicillin and amoxycillin. On the 
average for each generic medication we found 1.6 brand names. Questions raised 
here include: why so many generics hidden under different brand names? What 
about scarce resources and the health budget, considering that we have estimated 
a total cost of 70 million US Dollars for the purchase of medications during that 
year? What about confusion in prescribing and impact on the consumer? 
 
 
 
3. Defining a package as being composed of 20 tablets/capsules, six 
suppositories, five injections or one bottle of drops or liquid, at least 25 million 
packages, or over 500 million tablet/capsule equivalents, were sold/dispensed in 
the area during 1991.  That is, average sales/consumption was found to be at 
least 12 packages - or 250 tablet/capsule equivalents- per person per year. The 
question is: is this consumption/sale necessary? What does this do to the 
individual family budgets? To the economy? What about un-necessary use and 
side effects? 
 
4. Although WHO and other world authorities on the manufacturing and use of 
drugs do not recommend the production of fixed dose combination drugs, 
because of potential therapeutic problems as well as cost, nevertheless, we found 
the medication market in the country full of fixed does combinations: 
 
* Of the total brands produced by the local industry, 49% were composed of 
fixed dose combinations 
* Of the total sales if Israeli brands, 36% were composed of fixed dose 
combinations 
* of the total sales of international brands, 35% were composed of fixed dose 
combination 
 
Overall, 41% of all available medications in the country were found to be of the 
fixed- dose combination. Yet, 97% of the Essential Drug List produced by WHO 
are single ingredient medications. 
 
It should be mentioned here that, other than un-necessary costs because fixed 
dose combinations are more expensive than single active ingredient products,  
some of the fixed dose combinations available in this country are irrationally 
mixed and are a potential hazard to the health. For instance: 
 
a. Antibiotics are mixed with corticosteroids, where the corticosteroids are 
known to potentially mask the side effects of antibiotics. Mixing them is bad 
practice 
b. Expectorants are mixed with antitussives, when one compound counteracts the 
effects of the other and therefore makes an irrational combination 
c. Hypnotics are mixed with muscle relaxants and narcotics, posing the potential 
problem of potentiating side effects 
d. Different vitamins are mixed together in irrational combinations and with 
highly questionable dosages. 
 
 
 
The question that must be raised is: why produce and prescribe fixed dose? Is it 
because we are used to doing it without thinking, when, clearly, their utility is 
very limited and there cost adds substantially to the health care costs of the 
country, let alone the problem of potentiating side effects? 
 
5. The question of un-necessary consumption of useful but potentially dangerous 
medications was also raised by examining lists of the most commonly sold 
medications in the country. 
 
* For the local industry, the singlemost commonly sold consumed medication 
was antibiotics, with a high of 23% of the total sales, followed by analgesics, 
with 14% of total sales, 12% for dermatological preparations, 9% for 
non-steroidal anti-inflamatory agents , 5% for cough and cold medications, 5% 
for nutritional supplements, eye, nose and ear drops respectively, 4% for 
antispasmodics and 2% for antacids and antihistamines, antihypertensives, 
asthma preparations and ulcer medications. 
* For the Israeli industry, the single most commonly sold/consumed medication 
was nutritional supplements with 20%, followed by antibiotics, with 12%, 
analgesics with 12%, cardiovascular drugs with 8%, laxatives with 6%, and 
NSAID's with 5%. 
* For the international products, the singlemost commonly sold/consumed 
medication was dermatologic preparations with 15% of the total sales, followed 
by 10% for antibiotics, 8% for nutritional supplements, 6% for hormones and 
ENE drops, 5% for cardiovascular medications and cough and cold mixtures and 
4% antihypertensive medications. 
 
That is... these results raise a few key questions: 
 
a. Are we prescribing/consuming antibiotics rationally? How does this very high 
level of use of antibiotic affect the problem of increasing resistance? How does 
this affect national health expenditure? Can we afford such practices? And how 
does this eventually affect the patient? Is this good practice? 
b. Why are we prescribing medications with an acknowledged limited utility 
such as nutritional supplements, in such high quantities unwarranted by good 
medical practice? What does this do to the national level of expenditure on 
health? 
 
4. Finally, among the many other questions raised by this study, the question of 
the production and consumption of banned and un-necessary medications was 
raised: 
 
 
There were several chemical compounds that are banned in different parts of the 
world and considered dangerous and that continue to be used as medications 
locally, sometimes in alarming quantities: 
 
a. Dipyrone or novaminsulfone (antipyretic analgesic). Over 4.4 million tablets 
of this dangerous medication were sold/consumed during 1991 
b. The quinolines: clioquinol, iodochorohydroxyquine and 
di-iodohydroxyquinoline(anti-diarrhoeals). These dangerous medications 
associated with severe neurological sequale, and un-documented efficacy, where 
WHO warns against there use, and where they are banned in many parts of the 
world, are heavily used locally: with 100000 packages sold during 1991. 
c. Opiates and anti-motility agents, such as diphenoxylate and loperamite, and 
wrongly used for the treatment of diarrhoea. WHO maintains that they can be 
very dangerous and that they are of no use in the prevention and treatment of 
dehydration. Yet 14000 packages were sold/consumed during the year 
d. Furazolidine: again for the treatment of diarrhoea, with no established use and 
potentially harmful 
e. Chloramphenicol: again 650000 capsules sold during a year, totally unjustified 
by very specific and selected use of this medication with dangerous side effects 
f. The butazones: such as oxyphenbutazone and phenylbutazone. Can cause fatal 
blood complications, banned in many countries, but with 92800 packages sold 
here during 1991. 
 
The question is: why are we contributing to the ill health of people and 
burdening the individual and national budgets with these dangerous 
expenditures? Is this what good medical practice indicates? Is it not our duty, 
after all the oaths we have taken, to inform ourselves regularly and maintain the 
utmost care when prescribing and dispensing these dangerous drugs? 
 
In summary, then, there is a pressing need to develop adequate rational drug use 
and manufacturing policies for this country today: 
 
1. On the one hand, the local industry must be strengthened through upgrading, 
quality control and the production of rationally mixed and useful medications. At 
the moment, the industry packages and mixes medication. We desperately need 
upgrading that would allow for synthesis as well, difficult and gradual as it may 
be. This is needed in order to assist in the improvement of the health of people 
through the production of needed, and rationally mixed medications, maintaining 
costs at the lowest levels possible. But it is also needed in order to gradually 
decrease our dependence on the outside world and begin to build a  
 
national industry that would not only contribute to the health sector but to the 
economy as a whole as well. 
2. On the other hand, we are desperately in need for the development of a local 
essential drug and standard drugs list. This is not merely a health requirement, 
but also an economic necessity. Palestinians are increasingly facing an 
economically restrained environment. We must begin to re-build thinking also 
about minimizing costs, while providing the needed medications to the 
population. This is crucial in view of the observation that between 30-40% of 
primary health care costs go to medications. 
3. On the third hand, a good amount of professional and public education is 
needed in order to begin to raise awareness as to the potential dangers of abusing 
these medications, in relation to  both the individual and the public. 
4. Finally, more investigations are needed in order to identify and elaborate 
specific problems in drug consumption and use. Such studies can be crucial for 
future policy formulation as well as for professional and public education. 
